Abcam (OTCMKTS:ABCZY) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Monday.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Abcam (ABCZY) traded up $0.45 during midday trading on Monday, hitting $16.92. The stock had a trading volume of 1,400 shares, compared to its average volume of 868. Abcam has a one year low of $9.76 and a one year high of $16.75.

COPYRIGHT VIOLATION NOTICE: This story was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.thecerbatgem.com/2018/01/22/abcam-abczy-cut-to-hold-at-zacks-investment-research.html.

Get a free copy of the Zacks research report on Abcam (ABCZY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.